GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » J.Molner AS (OTSE:MOLNR) » Definitions » FCF Margin %

J.Molner AS (OTSE:MOLNR) FCF Margin % : -487.90% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is J.Molner AS FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. J.Molner AS's Free Cash Flow for the six months ended in Dec. 2023 was €-1.69 Mil. J.Molner AS's Revenue for the six months ended in Dec. 2023 was €0.35 Mil. Therefore, J.Molner AS's FCF Margin % for the quarter that ended in Dec. 2023 was -487.90%.

As of today, J.Molner AS's current FCF Yield % is -11.82%.

The historical rank and industry rank for J.Molner AS's FCF Margin % or its related term are showing as below:

OTSE:MOLNR' s FCF Margin % Range Over the Past 10 Years
Min: -428.32   Med: -371.45   Max: -314.58
Current: -428.32


During the past 3 years, the highest FCF Margin % of J.Molner AS was -314.58%. The lowest was -428.32%. And the median was -371.45%.

OTSE:MOLNR's FCF Margin % is ranked worse than
93.97% of 1028 companies
in the Drug Manufacturers industry
Industry Median: 0.06 vs OTSE:MOLNR: -428.32


J.Molner AS FCF Margin % Historical Data

The historical data trend for J.Molner AS's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

J.Molner AS FCF Margin % Chart

J.Molner AS Annual Data
Trend Dec21 Dec22 Dec23
FCF Margin %
- -314.58 -428.32

J.Molner AS Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
FCF Margin % - - - -352.03 -487.90

Competitive Comparison of J.Molner AS's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


J.Molner AS's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's FCF Margin % distribution charts can be found below:

* The bar in red indicates where J.Molner AS's FCF Margin % falls into.



J.Molner AS FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

J.Molner AS's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-2.647/0.618
=-428.32 %

J.Molner AS's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-1.693/0.347
=-487.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


J.Molner AS FCF Margin % Related Terms

Thank you for viewing the detailed overview of J.Molner AS's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


J.Molner AS (OTSE:MOLNR) Business Description

Traded in Other Exchanges
N/A
Address
Akadeemia tee 21/5, Harju maakond, Tallinn, EST, 12618
J.Molner AS is an Estonia-based company. The company is engaged in research and development in the field of biotechnology. The activities of the Company are divided into two fields: 1) Chemistry analytical and development services for third parties; 2) Development of the Company's own line of generic pharmaceuticals.

J.Molner AS (OTSE:MOLNR) Headlines

No Headlines